Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.37 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
| ▸ | NMT2 | O60551 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18715477 | 0.92 | GLP1R (0.47) | GLP1RLPAR3TLR2MEN1KMT2A | |
| SCHEMBL18715474 | 0.92 | GLP1R (0.47) | GLP1RLPAR3TLR2MEN1KMT2A | |
| SCHEMBL22172474 | 0.92 | GLP1R (0.41) | GLP1RLPAR3TLR2MEN1KMT2A | |
| SCHEMBL20375472 | 0.90 | GLP1R (0.46) | GLP1RLPAR3TLR2MEN1KMT2A | |
| SCHEMBL20375605 | 0.89 | GLP1R (0.47) | GLP1RLPAR3TLR2MEN1KMT2A | |
| SCHEMBL20814382 | 0.89 | GLP1R (0.47) | GLP1RLPAR3TLR2MEN1KMT2A | |
| SCHEMBL18715649 | 0.89 | GLP1R (0.54) | GLP1RLPAR3TLR2LPAR1NMT2 | |
| SCHEMBL23714584 | 0.89 | GLP1R (0.46) | GLP1RLPAR3TLR2MEN1KMT2A | |
| SCHEMBL21287433 | 0.86 | GLP1R (0.46) | GLP1RLPAR3TLR2MEN1KMT2A | |
| SCHEMBL22566714 | 0.86 | GLP1R (0.44) | GLP1RLPAR3TLR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056454-A1 | RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-02-24 | — | — | US | disclosed |
| US-20210285000-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | Janssen Pharmaceuticals, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-10995335-B2 | RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200330499-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | Janssen Pharmaceuticals, Inc. (US) | 2020-10-22 | — | — | US | disclosed |
| US-10450565-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190078089-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-03-14 | — | — | US | disclosed |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| US-9932586-B2 | Compositions and methods for inhibiting gene expression of LPA | Arrowhead Pharmaceuticals, Inc. (US) | 2018-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056454-A1 | RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use | HSD17B13, HSD17B3, HSD17B10 | GLP1R 3037/4885LPAR3 1424/4885TLR2 4146/4885 |
| US-10995335-B2 | RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use | TEK, PLIN3, PNLIP | GLP1R 459/4885LPAR3 123/4885TLR2 3137/4885 |
| US-10450565-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885LPAR3 3281/4885TLR2 4582/4885 |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885LPAR3 3281/4885TLR2 4582/4885 |
| US-20210285000-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | HAVCR2, EIF2AK2, IFNAR1 | GLP1R 4338/4885LPAR3 1993/4885TLR2 1335/4885 |
| US-20200330499-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | HAVCR2, HCCS, EIF2AK2 | GLP1R 4386/4885LPAR3 1483/4885TLR2 3384/4885 |
| US-20190078089-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | TEK, PLIN3, PNLIP | GLP1R 459/4885LPAR3 123/4885TLR2 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.